Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Germany far'IF' movie review: John Krasinski’s film hits a box office nerve with $35 million debutIt's so hot in Mexico that howler monkeys are falling dead from the treesReport says China is accelerating the forced urbanization of rural TibetansUK court rules that extension of UK police powers to intervene in protests is unlawfulClosing prices for crude oil, gold and other commoditiesChina sanctions former US lawmaker who supported TaiwanGarcia, Winker go deep as Nats end slide, beat struggling Twins 12It's so hot in Mexico that howler monkeys are falling dead from the treesTrump visits Minnesota after son Barron's Florida high school graduation
2.5933s , 6497.7734375 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,World Wave news portal